Illumina, Inc. (ILMN) News
Track canonical SquawkNews coverage tagged to ILMN, Illumina, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 40 indexed stories across 21 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Illumina Is Maintained at Outperform by Leerink Partners
Ratings actions from Benzinga: GMT) Illumina Price Target Raised to $300.00/Share From $220.00 by Leerink PartnersRatings actions from Benzinga
NEWS | Sep 29, 2026, 04:35 PM UTC
L
Illumina Price Target Raised to $305.00/Share From $225.00 by Piper Sandler
Ratings actions from Benzinga: GMT) Illumina Is Maintained at Overweight by Piper SandlerRatings actions from Benzinga
NEWS | Sep 28, 2026, 04:11 PM UTC
L
Grail Is Maintained at Buy by Canaccord Genuity
Ratings actions from Benzinga: GMT) Grail Price Target Raised to $150.00/Share From $80.00 by Canaccord GenuityRatings actions from Benzinga
NEWS | Sep 28, 2026, 12:50 PM UTC
H
Oracle, Qualcomm, Meta, Everpure, BlackBerry, MGM, Nebius, and More Stocks That Explain Today's Market — Barrons.com
By George Glover, Mariapaula Gonzalez, and Connor SmithStocks were mixed Thursday as the bond market's woes worsened and following a report that signaled potential progress in discussions between the U.S. and Iran.Oracle
GEOPOLITICS | Sep 24, 2026, 08:39 PM UTC
L
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test
By Elias SchisgallShares of Grail rose after the healthcare company said a U.S. regulatory committee voted to approve its Galleri multi-cancer early detection test.The stock was up 5.6% at $114.59 as of midday Thursday.
REGULATION | Sep 24, 2026, 04:23 PM UTC
L
Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN
SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 23, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.Alpha Teknova Inc. (TKNO)Alpha T
NEWS | Sep 24, 2026, 09:42 AM UTC
L
GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness
A U.S. Food and Drug Administration (FDA) advisory panel on Wednesday backed GRAIL’s Galleri multi-cancer blood test for adults aged 50 and older, voting that it looks safe and that its benefits outweigh its risks, while
REGULATION | Sep 23, 2026, 11:53 PM UTC
L
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
A panel of outside experts advising the US FDA backed the safety of Grail's NASDAQ:GRAL blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence supporting its effectiveness.W
REGULATION | Sep 23, 2026, 09:43 PM UTC
L
Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test
By Colin KellaherTrading in shares of Grail is halted on Wednesday ahead of a Food and Drug Administration advisory committee meeting to discuss the diagnostic company's proposed multi-cancer blood test.Grail is seeking
REGULATION | Sep 23, 2026, 11:52 AM UTC
M
Grail shares surge ahead of FDA advisory meeting on documents
Shares of Grail surged 34% after the FDA released documents ahead of a Wednesday advisory committee meeting on whether the company’s multi-cancer blood test will be approved.
EQUITY | Sep 21, 2026, 10:57 PM UTC
M
Grail shares surge after FDA staff see no major test concerns
US FDA staff reviewers said they did not raise major concerns about the accuracy and safety of Grail’s multi-cancer blood test. Grail’s shares surged 35% on Monday.
EQUITY | Sep 21, 2026, 04:41 PM UTC
M
Grail stock jumps 33% ahead of FDA multi-cancer blood test review
Grail shares rose 33% ahead of an FDA advisory panel meeting this week to evaluate premarket approval for its blood test designed to detect multiple cancer types early.
EQUITY | Sep 21, 2026, 03:28 PM UTC
H
Illumina Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Illumina (NASDAQ: ILMN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcr
LIVE | Sep 18, 2026, 08:37 AM UTC
H
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE: LUXE ) rose sharply after the company reported fourth-quarter results. LuxExperience reporte
LIVE | Sep 16, 2026, 01:57 PM UTC
H
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The U.S. 10-year Treasury yield broke above 5% on Tuesday, and crude oil stormed past $105 a barrel, a combination that left every major U.S. equity index in the red at midday. President Donald Trump said on Truth Social
LIVE | Sep 15, 2026, 05:27 PM UTC
L
Illumina upgraded to Buy by UBS; price target raised to $260
UBS upgraded Illumina to Buy from Neutral and raised its price target to $260.00 per share from $135.00, according to Benzinga and TradingView News.
EQUITY | Sep 09, 2026, 01:38 PM UTC
L
UBS initiates buy on ILMN with $105 price target
UBS initiated a buy rating for ILMN and set a $105.00/Share price target.
EQUITY | Sep 09, 2026, 01:30 PM UTC
M
Bloom Energy set to join S&P 500 before Sept. 21
Bloom Energy Corp. is set to join the S&P 500 before the open on September 21, part of the quarterly rebalance, lifting it 5.63% premarket. Illumina and Everpure also join; ILMN up 1.04%, P up 2.70%.
EQUITY | Sep 08, 2026, 12:16 PM UTC
M
S&P 500 to add Bloom Energy, Everpure and Illumina Monday
S&P Dow Jones Indices said Bloom Energy (BE), Everpure (P) and Illumina (ILMN) will enter the S&P 500 before trading begins Monday, September 21, replacing existing constituents.
EQUITY | Sep 07, 2026, 09:46 PM UTC
M
BE, P and ILMN to join S&P 500 index
Bloom Energy shares jumped after-hours after S&P said on Friday that Bloom Energy (BE), Everpure (P) and Illumina (ILMN) will join its S&P 500, while Cheniere Energy (LNG) slipped.
EQUITY | Sep 04, 2026, 11:43 PM UTC
M
Bloom Energy to join S&P 500 in quarterly reshuffle
Bloom Energy is set to replace Molson… as the S&P 500 adds three new members this month, alongside Everpure and Illumina, in a quarterly reshuffle.
EQUITY | Sep 04, 2026, 10:16 PM UTC
L
AGNC Investment to Join S&P MidCap 400
AGNC Investment is set to join the S&P MidCap 400.
EQUITY | Sep 04, 2026, 09:27 PM UTC
L
Molson Coors to move from S&P 500 to S&P SmallCap 600 Sept. 21
Molson Coors is set to move from the S&P 500 to the S&P SmallCap 600 on Sept. 21.
EQUITY | Sep 04, 2026, 09:23 PM UTC
M
Bloom Energy, Illumina, and Everpure to join the S&P 500
Bloom Energy, Illumina, and Everpure are set to join the S&P 500.
EQUITY | Sep 04, 2026, 09:20 PM UTC
L
Illumina maintained at Buy by Argus Research
Argus Research maintained a Buy rating on Illumina, according to ratings actions cited by Benzinga.
EQUITY | Sep 03, 2026, 01:38 PM UTC
L
Novacyt S.A. master collaboration agreement with Illumina
Novacyt S.A. entered a master collaboration agreement with Illumina.
EQUITY | Sep 01, 2026, 06:01 AM UTC
L
Largest premium to VWAP COTY (+3.75%) TEM (+3.69%) ILMN (+3.3%) WHR (+2.89%) NDSN (+2.71%) RGEN (+2.55%) TPL (+2.49%) DG (+2.37%) LITE (+2.3
Largest premium to VWAP COTY (+3.75%) TEM (+3.69%) ILMN (+3.3%) WHR (+2.89%) NDSN (+2.71%) RGEN (+2.55%) TPL (+2.49%) DG (+2.37%) LITE (+2.36%) DE (+2.32%) (Russell 1000 names)
EQUITY | Aug 20, 2026, 03:22 PM UTC
L
Illumina guides FY revenue $4,600-4,640M
Illumina guides FY revenue higher
EARNINGS | Jul 30, 2026, 08:27 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
L
Illumina Raises FY2026 Adj EPS Guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 Est; Raises FY2026 Sales Guidance from $4.520B-$4.620B to $
Illumina (NASDAQ: ILMN ) raises FY2026 Adj EPS guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 analyst estimate. Raises FY2026 sales outlook from $4.520 billion-$4.620 billion to $4.600 billion-$4.640 billion vs $4.566
EARNINGS | Jul 30, 2026, 08:13 PM UTC
L
ILMN Q2 adj EPS $1.31 vs. est. $1.23; Q2 revs $1.16B vs. est. $1.13B; raises FY26 adjusted EPS view to $5.30-$5.40 from $5.15-$5.30 (est. $5
ILMN Q2 adj EPS $1.31 vs. est. $1.23; Q2 revs $1.16B vs. est. $1.13B; raises FY26 adjusted EPS view to $5.30-$5.40 from $5.15-$5.30 (est. $5.23) and boosts FY26 rev view to $4.6B-$4.64B from $4.52B-$4.62B (est. $4.57B);
EARNINGS | Jul 30, 2026, 08:12 PM UTC
L
ILMN Illumina RESULTS: Q2, Q2 ebit margin 21.1%, Q2 REV $1.159B vs. EST $1.130B, Q2 ADJ gross margin 68.2%, Q2 gross margin 66.4%, Q2 ADJ eb
ILMN Illumina RESULTS: Q2, Q2 ebit margin 21.1%, Q2 REV $1.159B vs. EST $1.130B, Q2 ADJ gross margin 68.2%, Q2 gross margin 66.4%, Q2 ADJ ebit margin 22.5%, Q2 ADJ EPS $1.31 vs. EST $1.23, Illumina Earnings Notes:, - Ill
EARNINGS | Jul 30, 2026, 08:08 PM UTC
L
ILMN ILMN ILMN - Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
ILMN ILMN ILMN - Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
EARNINGS | Jul 30, 2026, 08:06 PM UTC
H
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.5%, RIVN +/-7.9%, NXT +/-16.8%, MTZ +/-14.6%, AJG +/-7.2%, GH +/-14.1%, CTVA +/-
EARNINGS | Jul 30, 2026, 05:58 PM UTC
H
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
EARNINGS | Jul 21, 2026, 12:30 PM UTC
L
ILMN Element Biosciences Prevails in German Patent Case Against Illumina Element Biosciences Prevails in German Patent Case Against Illumina
ILMN Element Biosciences Prevails in German Patent Case Against Illumina Element Biosciences Prevails in German Patent Case Against Illumina Munich Regional Court finds Illumina infringes Element sequencing intellectual
EQUITY | Jul 14, 2026, 12:11 PM UTC
L
Illumina shares are trading higher after Piper Sandler maintained its Overweight rating on the stock and raised its price target from $170 t
Illumina shares are trading higher after Piper Sandler maintained its Overweight rating on the stock and raised its price target from $170 to $200.
EQUITY | Jul 01, 2026, 06:34 PM UTC
L
Piper Sandler Maintains Overweight on Illumina, Raises Price Target to $200
Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ: ILMN ) with a Overweight and raises the price target from $170 to $200.
EQUITY | Jul 01, 2026, 11:52 AM UTC
M
ILMN: Bernstein Reinstates
Bernstein reinstates Illumina with a Market Perform rating and $185 price target
EQUITY | Jun 26, 2026, 01:37 PM UTC
M
ILMN Raised to $145
Illumina shares are trading higher after Barclays raised its price target on the stock from $122 to $145.
EQUITY | Jun 24, 2026, 03:19 PM UTC